NICE recommends Sobi's Xiaflex in FAD

The U.K.'s NICE issued a final appraisal determination (FAD) recommending the use of Xiapex collagenase clostridium histolyticum from Swedish Orphan Biovitrum AB (SSE:SOBI) to treat Dupuytren's disease in adults with a palpable cord who are not enrolled in a clinical trial comparing Xiapex to limited fasciectomy. Specifically, patients can be considered for treatment: if there is evidence of moderate disease plus up to two affected joints; percutaneous needle fasciotomy is not considered appropriate except when recommended by the treating hand surgeon; the choice of treatment is made between the patient and the surgeons; and one injection is given per treatment session by a hand surgeon in an outpatient setting...